215
Participants
Start Date
March 19, 2013
Primary Completion Date
May 31, 2016
Study Completion Date
January 23, 2025
Nilotinib followed by treatment-free
Nilotinib is being used as commercial available capsules (except in Japan where clinical supplies is used) of 150 mg and 200 mg strength. Treatment occurs during consolidation, continuation, prolonged continuation, re-initiation and re-initiation-2 phases of the study.
Novartis Investigative Site, Brussels
Novartis Investigative Site, Vienna
Novartis Investigative Site, Brussels
Novartis Investigative Site, Liège
Novartis Investigative Site, Salzburg
Novartis Investigative Site, Charleroi
Novartis Investigative Site, Szeged
Novartis Investigative Site, Graz
Novartis Investigative Site, Aarhus N
Novartis Investigative Site, Kortrijk
Novartis Investigative Site, Ghent
Novartis Investigative Site, Varna
Novartis Investigative Site, Sint-Niklaas
Memorial Sloan Kettering, New York
Novartis Investigative Site, Orbassano
Novartis Investigative Site, Galway
Novartis Investigative Site, Berlin
Novartis Investigative Site, Genova
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Lübeck
Novartis Investigative Site, Brescia
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Novara
Cancer Centers of the Carolinas, Greenville
Novartis Investigative Site, Brest
Novartis Investigative Site, Pamplona
Novartis Investigative Site, Toulouse
Novartis Investigative Site, Ourense
Novartis Investigative Site, Oviedo
Lakes Research, Miami Lakes
Novartis Investigative Site, Bordeaux
H Lee Moffitt Cancer Center and Research Institute, Tampa
Florida Cancer Specialists, Fort Myers
Novartis Investigative Site, Las Palmas de Gran Canaria
Tennessee Oncology PLLC, Chattanooga
Novartis Investigative Site, Grenoble
Novartis Investigative Site, San Cristóbal de La Laguna
Novartis Investigative Site, Goslar
Novartis Investigative Site, Magdeburg
Novartis Investigative Site, Düsseldorf
Novartis Investigative Site, Düsseldorf
Novartis Investigative Site, Saint Priest En Jarez
Novartis Investigative Site, Tarragona
Novartis Investigative Site, Nantes
Novartis Investigative Site, Cona
Novartis Investigative Site, Bottrop
Novartis Investigative Site, Barakaldo
Novartis Investigative Site, Florence
Novartis Investigative Site, Aachen
Novartis Investigative Site, Bonn
Novartis Investigative Site, Mainz
Novartis Investigative Site, Dunkirk
Novartis Investigative Site, Ancona
Novartis Investigative Site, Frankfurt am Main
Novartis Investigative Site, Bayonne
Novartis Investigative Site, Strasbourg
Novartis Investigative Site, Strasbourg
Novartis Investigative Site, Mannheim
Novartis Investigative Site, Stuttgart
Novartis Investigative Site, Rouen
Novartis Investigative Site, Freiburg im Breisgau
Novartis Investigative Site, Napoli
Community Cancer Trials of Utah, Ogden
Novartis Investigative Site, Ulm
Novartis Investigative Site, Reggio Calabria
Novartis Investigative Site, Corbeil-Essonnes
Novartis Investigative Site, Bayreuth
Oregon Health Sciences University, Portland
Novartis Investigative Site, Bogota
Novartis Investigative Site, Montería
Cancer Center of Kansas, Wichita
Dana Farber Cancer Institute, Boston
Novartis Investigative Site, Buenos Aires
Novartis Investigative Site, Rankweil
Novartis Investigative Site, Vienna
Novartis Investigative Site, Leipzig
Novartis Investigative Site, Jena
Novartis Investigative Site, Dresden
Novartis Investigative Site, Athens
Novartis Investigative Site, Athens
Novartis Investigative Site, Budapest
Novartis Investigative Site, Dublin
Novartis Investigative Site, Nuoro
Novartis Investigative Site, Perugia
Novartis Investigative Site, Roma
Novartis Investigative Site, Terni
Novartis Investigative Site, Kashiwa
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Sagamihara
Novartis Investigative Site, Ōsaka-sayama
Novartis Investigative Site, Suita
Novartis Investigative Site, Saga
Novartis Investigative Site, Kawagoe
Novartis Investigative Site, Shimotsuga Gun
Novartis Investigative Site, Bunkyo-ku
Novartis Investigative Site, Shinjuku Ku
Novartis Investigative Site, Akita
Novartis Investigative Site, Kumamoto
Novartis Investigative Site, Groningen
Novartis Investigative Site, Gdansk
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Terrassa
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Lund
Novartis Investigative Site, Stockholm
Novartis Investigative Site, Uppsala
Novartis Investigative Site, Cardiff
Novartis Investigative Site, Oxford
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY